Evidence map›Paper›PMID 38983150›Full record

ArticleJournal of thoracic disease2024

Analysis of the resistance profile of real-world alectinib first-line therapy in patients with

Yingbo Xie, Yuxin Zhang, Yongqing Wu, Xiaohong Xie, Xinqing Lin, Qing Tang, Chengzhi Zhou, Zhanhong Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yingbo Xie *Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Health, Guangzhou, China.ORCID https://orcid.org/0009-0000-7681-0147
Yuxin Zhang *Department of Ultrasound Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yongqing WuDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Health, Guangzhou, China.
Xiaohong XieDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Health, Guangzhou, China.
Xinqing LinDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Health, Guangzhou, China.
Qing TangDepartment of Ultrasound Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Chengzhi ZhouDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Health, Guangzhou, China.
Zhanhong XieDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Diseases, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory, Guangzhou Institute of Respiratory Health, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alectinib has achieved excellent therapeutic efficacy in anaplastic lymphoma kinase ( Methods: Clinical data of patients with advanced NSCLC who received first-line alectinib treatment in the First Affiliated Hospital of Guangzhou Medical University between November 2018 and April 2022 were collected. Moreover, next-generation sequencing (NGS) data of the patient's baseline and post-resistance tissues were gathered. One patient underwent lung cancer organoid culture and drug sensitivity testing. Results: Out of 35 first-line alectinib-treated patients with advanced NSCLC, 31 are presently in progression-free survival (PFS; 4.3-35.0 months). Four patients experienced progressive disease, and all of them were sequentially treated with ceritinib. Tissue NGS results before sequential treatment in three patients indicated an echinoderm microtubule-associated protein-like 4- Conclusions: For

Indexed as

Alectinibanaplastic lymphoma kinase (ALK)drug sensitivity testingnon-small cell lung cancer (NSCLC)organoid

Identifiers

PMID38983150
PMCPMC11228735

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.